See the DrugPatentWatch profile for Abreva
The generic name for Abreva is docosanol [1]. Docosanol is an over-the-counter antiviral medication used to shorten the healing time of cold sores [1]. It works by preventing the herpes simplex virus from entering healthy cells [1].
How does docosanol work to treat cold sores?
Docosanol works by inhibiting the fusion of the host cell membrane with the viral envelope of the herpes simplex virus. This process prevents the virus from entering healthy cells and replicating, thereby helping to shorten the healing time of cold sores [1].
When might Abreva (docosanol) patent protection expire?
Information regarding the specific patent expiration dates for Abreva (docosanol) can be found on DrugPatentWatch.com [2]. Patent exclusivity is crucial for drug manufacturers, and its expiration can open the door for generic versions of medications.
Can generic versions of Abreva be sold before patent expiration?
Generally, generic versions of a medication cannot be legally marketed until the relevant patent protections have expired. The expiration of these patents allows other pharmaceutical companies to produce and sell their own versions of the drug, often at a lower cost.
Where can I find more information on Abreva's drug patents?
DrugPatentWatch.com provides detailed information on drug patents, including those related to Abreva and its active ingredient, docosanol [2]. This resource is valuable for understanding the intellectual property landscape surrounding medications.
What are the active ingredients in Abreva?
The active ingredient in Abreva is docosanol [1].
Sources:
[1] https://www.webmd.com/drugs/2/227957/abreva/details
[2] https://www.drugpatentwatch.com